Trial Profile

A Phase 1 Single Centre, Single Ascending Dose Safety Study of GEH200486 in Healthy Volunteers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GE-200486 (Primary)
Indications Unspecified
Focus Adverse reactions; First in man
Sponsors GE Healthcare

Most Recent Events

07 Oct 2024 According to GE Healthcare Media Release, Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway.
07 Oct 2024 Results presented in the GE Healthcare Media Release.
01 Mar 2023 Status changed to active, no longer recruiting, according to a GE Healthcare media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com